Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach.
Nyberg F, Askling J, Berglind N, Franzén S, Ho M, Holmqvist M, Horne L, Lampl K, Michaud K, Pappas DA, Reed G, Symmons D, Tanaka E, Tran TN, Verstappen SM, Wesby-van Swaay E, Yamanaka H, Greenberg JD.
Nyberg F, et al. Among authors: pappas da.
Pharmacoepidemiol Drug Saf. 2015 Nov;24(11):1121-32. doi: 10.1002/pds.3854. Epub 2015 Aug 25.
Pharmacoepidemiol Drug Saf. 2015.
PMID: 26303866